MHMohamed Ahmed Hussein

Mohamed Ahmed Hussein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed Ahmed Hussein has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Gaafar Ragab

    Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University , Giza

    4 shared publications
  • Mary Wadie Fawzy

    Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Cairo University, Cairo, Egypt

    2 shared publications
  • Nagwa Abd El Ghaffar

    Clinical Pathology, National Research Center, Cairo, Egypt

    2 shared publications
  • Yumn A. Elsabagh

    Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Cairo University, Cairo, Egypt

    2 shared publications
  • Abdullah Osama Mahfouz

    Department of Cardiothoracic Surgery, Faculty of Medicine, Fayoum University, Fayoum, Egypt

    1 shared publication
  • Ahmed A. Dahab

    Ophthalmology Department, Cairo University, Cairo, Egypt

    1 shared publication

Latest Publications

  • Open Access

    ‘Vasculo’ & ‘Oculo/Neuro’ Behçet’s Disease: Two Opposing Sides of the Same Coin with Possible Different Pathogenesis

    by Mohamed A. Hussein

    Introduction: Prognosis of vasculo-Behçet’s disease (VBD) is not consistent. Patients exhibiting arterial and central large venous involvement have the poorest prognosis. Given the significance of risk stratification in the management of cardiovascular diseases and the lack of specific diagnostic tests for BD, which depends entirely on clinical manifestations, this study aimed to identify clinical features linked to high-risk VBD for early management and enhanced outcomes. Patients and Methods: Clinical characteristics of 230 BD patients; 96 VBD and 134 non-VBD; were documented and analysed. For risk stratification, VBD were categorised into two clinical groups. Group (A): 37 patients with isolated arterial and/or central large venous involvement(s) who were identified as having high-risk VBD (Hr-VBD), and Group (B) [low risk VBD (Lr-VBD)] comprised 59 patients with isolated peripheral limb deep venous thrombosis. Results: Retinal vasculitis and neuro-BD (NBD) were less frequent in Hr-VBD patients ( P = .03, .06, respectively). However, in multivariate analysis, only NBD was found to be less associated with Hr-VBD ( P = .08). A comparison of VBD and non-VBD validated the inverse relationship between retinal and peripheral vasculitis in both univariate ( P = .01) and multivariate ( P = .049) analyses. Moreover, anterior, posterior, and pan-uveitis were all significantly lower in VBD in univariate ( P = .01, <.001 and .03) and multivariate (.03, .001 and .045) examination. Furthermore, male gender ( P = .01) and disease duration ( P = .045) were associated with VBD. Conclusion: Ocular and NBD are less associated with VBD, and when they co-occur, VBD tends to be of low risk with consequent better prognosis. BD seems to have two distinct opposing pathologies: central ‘oculo and NBD’ and peripheral vasculitis.


  • Atherosclerosis Associated With COVID-19: Acute, Tends to Severely Involve Peripheral Arteries, and May be Reversible

    by Eman O. Mahmoud, Yumn A. Elsabagh, Nagwa Abd El Ghaffar, Mary Wadie Fawzy, Mohamed A. Hussein

    Arterial stiffness was reported with corona virus disease 2019 (COVID-19). We studied atherosclerosis in COVID-19 directly through duplex ultrasound measurements and their relation to co-morbidities, clinical and laboratory severity markers, and serum interleukin (IL) 6 and 17. Serum IL 6 and 17, average carotid intima-media thickness (cIMT), diameter and peak systolic velocities (PSV) of tibial, ulnar, radial arteries, and ankle brachial index (ABI) were measured in 44 COVID-19 patients and 44 healthy controls. Serum IL6, IL17, PSV, and cIMT were higher while diameter was lower ( P ≤ .01) in cases. Clinical severity index correlated positively with age, co-morbidities, ferritin, IL6, IL17, cIMT, and PSV ( P ≤ .04) and negatively with diameter and ABI ( P = .04). Patients with severe lymphopenia had higher PSV, IL6, and IL17 and lower diameter ( P < .00001). Ferritin positively correlated with PSV and negatively with diameter and ABI ( P ≤ .01). Those who received an IL6 inhibitor (tocilizumab) showed lower PSV and higher diameter ( P ≤ .01). In multiple regression analysis, IL17 and (age, co-morbidities) were related to (PSV, diameter) and cIMT ( P ≤ .001, ≤0.02), respectively. COVID-19 may be associated with subclinical acute and may be reversible atherosclerosis severely involving peripheral arteries.


  • Open Access

    Proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis: A marker of disease activity and severe disease manifestations with potential therapeutic implementations

    by Joy Artin, Yumn A. Elsabagh, Laila Rashed, Mohamed A. Hussein

    Objectives: This study aims to investigate proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis (d-SSc) and its relation to disease activity, severity and subclinical atherosclerosis in such group of patients. Patients and methods: Between December 2019 and July 2021, a total of 41 patients with d-SSc (17 males, 24 females; mean age: 36.1±1.9 years; range, 19 to 58 years) and 41- age and sex-matched healthy controls (17 males, 24 females; mean age: 40.1±1.7 years; range, 20 to 60 years) were included. Disease activity and skin thickness of the patients were evaluated using the European Scleroderma Study Group (EScSG) score and modified Rodnan skin score (mRSS), respectively. Serum PCSK9 and carotid intima-media thickness (CIMT) were measured using enzyme-linked immunosorbent assay (ELISA) and Duplex ultrasound, respectively. Results: Serum PCSK9 was higher in patients compared to controls (p=0.003), particularly in those with digital ulcer (DU) and interstitial lung disease (ILD) (p


  • Open Access

    Evaluation of Levosimendan in Patients with High Risk Severe Mitral Valve Disease Undergoing Mitral Valve Surgery

    by Ahmed M. Elwakeel, Alaa M. Omar, Mohamed A. Hussein, Ehab M. Elshihy, Abdullah Osama Mahfouz

    Background: Levosimendan has anti-ischemic effects, improves myocardial contractility and increases systemic, pulmonary and coronary vasodilatation. Objectives: The present study investigated the perioperative hemodynamic effects of a prophylactic infusion of levosimendan in high-risk mitral valve surgery patients with left ventricle dysfunction, and compared short-term clinical outcomes with a control group in which levosimendan wasn’t used. Patients and methods: BetweenOctober 2019 and May 2021, a prospective randomized clinical study was performed in 100 patients with high-risk mitral valve surgery with left ventricular dysfunction and pulmonary hypertension. In the study group, patients received levosimendan infusion at a dose of 0.1 mcg/kg/min after the induction of anesthesia while in control group levosimendan was not used. The intraoperative and postoperative data were recorded for each patient in both groups. The hemodynamic measurements were performed at six predetermined time points (0, 1, 6, 12, 24 and 36 hours postoperatively). Results: Levosimendan had significantly improved postoperative hemodynamic values. It improved mean arterial pressure at different times postoperatively (p < 0.05), heart rate at different times postoperatively (p < 0.05). Also, levosimendan preserved LV systolic performance postoperatively (pulmonary artery pressure (PAP): 51.7 ± 6.4, 57.9 ± 8.6, P<0.001) and (ejection fraction (EF): 37.1 ± 9.3, 33.4 ± 7.1, P=0.03). Conclusion: Prophylactic levosimendan improved the hemodynamics in high-risk mitral valve surgery patients. So levosimendan seems to be a safe and effective choice for preventing left ventricular failure in high-risk mitral valve surgical patients with LV dysfunction.

  • P140 Transoral incisionless fundoplication using the EsophyX Z+ device: a UK first experience

    by Nasar Aslam, Vinay Sehgal, Mohamed Hussein, Rami Sweis, Laurence Lovat, Rehan Haidry

    Introduction Gastroesophageal reflux disease (GORD) is becoming increasingly prevalent in the western world. Lifestyle modification and medical therapy remain first line interventions, although anti-reflux surgery remains a choice in select individuals. Advances in endoscopic anti-reflux procedures have shown promise as an additional treatment option. Here we present the first UK experience of treating patients with confirmed GORD with Transoral incisionless fundoplication (TIF) 2.0 using the EsophyX Z+ device. Methods Data was collected retrospectively from 46 patients who underwent TIF 2.0 between November 2019 and February 2022 at a specialist centre. GERD-Health-Related Quality of Life (GERD-HRQL) questionnaires were used to evaluate treatment response. Results TIF 2.0 was performed in 46 patients, (29 male and 17 Female). The mean patient age at the time of procedure was 50 ± 17.3 years. Baseline physiology metrics following 96-hour BRAVOTM reflux testing were available for 38 patients. The mean DeMeester score at baseline was 31.62 ± 15.4. The median acid exposure time (% time pH Conclusions This represents UK’s first experience of TIF 2.0. Our growing cohort of patients undergoing TIF corroborates recent published data showing that it is a safe and effective procedure. Further, in patients in whom we have follow up data, there is a clear improvement in quality-of-life metrics, thus highlighting its potential as a viable endoscopic treatment option for patients with troublesome GORD. Limitations to this study are the retrospective observational design, heterogenous follow up data with the possibility of self-selection bias in follow up questionnaires. This may impact the generalisability of results. Further collection of outcomes using standardised study protocols with a larger patient cohort from different centres will help build upon the UK experience.

  • Interleukin 37; a possible marker of arterial stiffness in Behçet's disease

    by Mohamed A. Hussein, Mostafa Mahmoud Ramadan, Manal Abd El Moneam, Hanan Abd El Halim, Nagwa Abd El Ghaffar, Mary Wadie Fawzy


  • Open Access

    FRI0281 MACRO AND MICRO-VASCULAR AFFECTION IN CORRELATION TO HLA-B51 IN EGYPTIAN PATIENTSWITH BEHÇET'S DISEASE

    by Manal Elmeniawy, Mary Fawzy, Noha Khalil, Mohamed Hussein, Mervat Behiry, Rasmia Elgohary, Reham Abdelghany, Samar Ali, Sahar Kamal, Manal Abdelrazek

    Background: Behçet’s disease is a multisystem inflammatory disorder with unknown etiology.HLA-B51 antigen has been known as a genetic factor associated with B D(1). Vascular involvement in Behcet has been widely described to affect large & medium vessels Vascular involvement in Behcet has been widely described to affect large & medium vessels however, few studies demonstrated micro vascular affection through nailfold capillaroscopy examination (2). Objectives: Objective was to highlights HLA role in different clinical presentation of BD, especially the vascular point of view. Methods: 40 Egyptian Behçet’s disease patients (according to the international study group of Behçet’s disease, 1990), and 30 age and sex matched healthy controls where enrolled in our study. All patients were subjected to history taking and clinical examination. BDCAF, CBC, ESR, CRP, liver function and lipid profile. Genetic typing HLA B51 by PCR, carotid intima media thickness, Capillriscopy of nail capillary fold and ankle brachial index were done to both patients and controls. Comparison of Doppler& capillaroscopy parameters between the studied groups Results: There was no statistically significant correlation between HLA B51 and systemic manifestations or disease activity or Doppler findings nor capillary parameters and morphology. There was statistically significant relation between HLA B51 and ankle brachial index. There was statistically significant difference between patients and controls in EDV, RI of the carotid artery, and arterial, venous limb of the capillary, also the capillary lobe and length with lower values in the patients. There was statistically significant difference between patients and controls in carotid intima media thickness with higher values in patients, insipte of the absence of significant difference in lipid. Conclusion: HLA B51 didn’t link to different clinical presentation in BD; it is related to peripheral arterial affection only. BD patients had poor arterial compliance and increased arterial stiffness, there is preclinical atherosclerosis in BD not to related to the level of lipid profile. References: [1] Marshall SE. bechet’s disease. Best Pract Res Clin Rheumatol. 2004 Jun 1;18(3):291–311. [2] Hegab S, Al-Mutawa S. Immunopathogenesis of Behçet’s Disease. Clin Immunol. 2000;96(3):174–86. Disclosure of Interests: None declared

  • Open Access

    Acetylcholine iontophoresis in diabetic patients with and without peripheral neuropathy: a potential therapeutic tool

    by Ibrahim Ismail Abu Zaid, Mohamed Ahmed Hussein, Gihan Samir Mousa, Amany Raafat Mohamed, Nagwa Mohamed Badr, Alaa A. Hamid

  • Open Access

    Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs

    by Mohamed Tharwat Hegazy, Walaa Ramadan Allam, Mohamed A. Hussein, Naguib Zoheir, Luca Quartuccio, Sherif F. El-Khamisy, Gaafar Ragab


  • Open Access

    Vision-Threatening Behcet’s Disease: Severity of Ocular Involvement Predictors

    by Mohammed A. Hussein, Iman M. Eissa, Ahmed A. Dahab

    Purpose. To examine and spot systemic findings commonly associated with a serious form of ocular Behcet’s disease. This could potentially help ophthalmologists categorize their patients based on future risk and plan treatment accordingly. Subjects and Methods. The data of 249 patients with Behcet’s disease were examined thoroughly. Correlations between systemic and ocular findings were recorded. Patients were further subgrouped by the authors as having a vision-threatening form of the disease or not. Regression analysis was done to spot predictors for a vision-threatening form of the disease. Results. The presence of systemic vasculitis and oral and genital ulcers in a patient with Behcet’s disease was found to be associated with a milder form of ocular affection or none at all and vice versa. Certain correlations between findings were also found. Conclusion. Certain findings in Behcet’s disease may act as predictors for the severity of ocular affection. Directing our attention to these factors by the internist and ophthalmologist can help plan the frequency of follow-up as well as the aggressiveness of treatment in patients with Behcet’s disease.